Scotiabank raised the firm’s price target on Alnylam (ALNY) to $342 from $338 and keeps an Outperform rating on the shares. The US approval of fitusiran is another milestone for the company’s growing royalty portfolio, the analyst tells investors. The firm has updated its model to reflect the approval as well as the final pricing.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Alnylam price target raised to $345 from $300 at Stifel
- Alnylam initiated with a Buy at Redburn Atlantic
- Alnylam presents new data from HELIOS-B Phase 3 trial
- Alnylam Pharma’s Growth Potential Boosted by FDA Approval of Qfitlia and Promising Clinical Results
- Alnylam announces FDA approval of Qfitlia for treatment of hemophilia A or B